Drug Use Evaluation of Ceftriaxone in Ras-Desta Memorial General Hospital, Ethiopia
Open Access
- 1 September 2020
- journal article
- research article
- Published by Taylor & Francis in Drug, Healthcare and Patient Safety
- Vol. ume 12, 161-168
Abstract
Background: Ceftriaxone is one of the most commonly used antibiotics due to its availability, wide spectrum of activity and low toxicity. However, irrational use of ceftriaxone is one of the current issues in most countries, especially developing ones. Objective: The aim of this study was to evaluate ceftriaxone utilization in different wards of Ras-Desta Memorial General Hospital (RDMGH) in Ethiopia. Methods: An institution-based retrospective cross-sectional study was conducted on randomly selected 1,079 patients who were admitted to RDMGH from May 2017 to April 2018. A structured data abstraction format was used to collect data from patients’ medical chart. Micromedex® drug interaction checker was used to identify significant drug–drug interactions, and national and international guidelines were used to evaluate the appropriateness of ceftriaxone use. The data were analyzed by using SPSS version 20.0. Results: Among the 1,079 patients enrolled, ceftriaxone was utilized by 601 (55.7%) patients, and these patients were considered for evaluation of appropriateness and subsequent analysis. Among 601 patients, ceftriaxone was used for therapeutic purpose in 362 (60.2%) patients; of which, 359 (99.2%) were for empiric therapy and the rest 239 (39.8%) were for prophylaxis. In the majority of the patients, the dose of ceftriaxone was 2g/day 472 (78.6%) and for a duration of 2– 7 days 409 (68.1%). Inappropriate use of ceftriaxone was observed among 237 (39.4%) patients with regard to indication, dose/frequency and duration. About half (49.3%) of the deviation from the guidelines was observed from surgical and gynecologic/obstetrics wards. Among the co-prescribed medications with ceftriaxone, ringer lactate, warfarin and heparin were found to have a significant drug–drug interaction. Conclusion: This study revealed that inappropriate use of ceftriaxone was high in RDMGH. This may increase the emergence of resistant pathogens which may lead to treatment failure and increase cost of therapy. Therefore, adherence to current evidence-based guidelines is recommended.Keywords
This publication has 13 references indexed in Scilit:
- Antimicrobial resistance and synergy in herbal medicineJournal of Herbal Medicine, 2016
- Evaluation of ceftriaxone utilization in medical and emergency wards of Tikur Anbessa specialized hospital: a prospective cross-sectional studyBMC Pharmacology and Toxicology, 2016
- Exploration of over the counter sales of antibiotics in community pharmacies of Addis Ababa, Ethiopia: pharmacy professionals’ perspectiveAntimicrobial Resistance & Infection Control, 2016
- Evaluation of Ceftriaxone utilization in internal medicine wards of general hospitals in Addis Ababa, Ethiopia: a comparative retrospective studyJournal of Pharmaceutical Policy and Practice, 2015
- Introduction to sample size calculationEducation in Medicine Journal, 2013
- Dramatic increase of third-generation cephalosporin-resistant E. coli in German intensive care units: secular trends in antibiotic drug use and bacterial resistance, 2001 to 2008Critical Care, 2010
- What is the “New Public Health”?Public Health Reviews, 2010
- The growing burden of antimicrobial resistanceJournal of Antimicrobial Chemotherapy, 2008
- Third generation cephalosporin use in a tertiary hospital in Port of Spain, Trinidad: need for an antibiotic policyBMC Infectious Diseases, 2004
- Ceftriaxone and cefotaxime use in Victorian hospitalsMedical Journal of Australia, 2002